Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Alicaforsen therapy in inflammatory bowel disease.

Barish CF.

Expert Opin Biol Ther. 2005 Oct;5(10):1387-91. Review.

PMID:
16197343
2.

Alicaforsen. Isis Pharmaceuticals.

Gewirtz AT, Sitaraman S.

Curr Opin Investig Drugs. 2001 Oct;2(10):1401-6. Review.

PMID:
11890355
4.

Biologic therapy for inflammatory bowel disease.

Ardizzone S, Bianchi Porro G.

Drugs. 2005;65(16):2253-86. Review.

PMID:
16266194
5.

Therapeutic approaches in inflammatory bowel disease based on the immunopathogenesis.

Siegmund B, Zeitz M.

Rocz Akad Med Bialymst. 2004;49:22-30. Review.

PMID:
15631310
6.

Antiadhesion molecule therapy in inflammatory bowel disease.

van Assche G, Rutgeerts P.

Inflamm Bowel Dis. 2002 Jul;8(4):291-300. Review.

PMID:
12131614
7.

Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.

Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL.

Aliment Pharmacol Ther. 2002 Oct;16(10):1761-70.

8.
9.

Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD.

Philpott JR, Miner PB Jr.

Expert Opin Biol Ther. 2008 Oct;8(10):1627-32. doi: 10.1517/14712598.8.10.1627 .

PMID:
18774928
10.

ISIS 2302. Oligo-TCS.

[No authors listed]

Drugs R D. 1999 Mar;1(3):265-7. No abstract available.

PMID:
10566042
11.

Safety of biologic therapy.

Blonski W, Lichtenstein GR.

Inflamm Bowel Dis. 2007 Jun;13(6):769-96. Review.

PMID:
17304581
12.

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.

Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR; ISIS 2302-CS9 Investigators..

Gut. 2002 Jul;51(1):30-6.

13.

Antisense oligonucleotide treatment of inflammatory bowel diseases.

Yacyshyn BR.

Methods Mol Med. 2005;106:295-305. Review. No abstract available.

PMID:
15375323
14.

Technology evaluation: alicaforsen (Isis).

Gewirtz AT, Sitaraman SV.

Curr Opin Mol Ther. 2005 Jun;7(3):273-81. Review.

PMID:
15977426
15.
16.

Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.

Miner PB Jr, Geary RS, Matson J, Chuang E, Xia S, Baker BF, Wedel MK.

Aliment Pharmacol Ther. 2006 May 15;23(10):1427-34.

17.

Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.

Miner PB Jr, Wedel MK, Xia S, Baker BF.

Aliment Pharmacol Ther. 2006 May 15;23(10):1403-13. Erratum in: Aliment Pharmacol Ther. 2006 Oct 15;24(8):1268.

18.

[Immunopathogenesis of inflammatory bowel diseases].

Neurath MF, Schürmann G.

Chirurg. 2000 Jan;71(1):30-40. Review. German.

PMID:
10662999
19.

Chemokines orchestrate leukocyte trafficking in inflammatory bowel disease.

Zhong W, Kolls JK, Chen H, McAllister F, Oliver PD, Zhang Z.

Front Biosci. 2008 Jan 1;13:1654-64. Review.

PMID:
17981657
20.

Signaling for inflammation and repair in inflammatory bowel disease.

Neuman MG.

Rom J Gastroenterol. 2004 Dec;13(4):309-16. Review.

PMID:
15624029

Supplemental Content

Support Center